Suppr超能文献

甲状腺手术后恶心和呕吐的药物干预:系统评价和网络荟萃分析。

Pharmacologic interventions for postoperative nausea and vomiting after thyroidectomy: A systematic review and network meta-analysis.

机构信息

Department of Anesthesiology and Pain Medicine, Chung-Ang University College of Medicine, Seoul, Republic of Korea.

出版信息

PLoS One. 2021 Jan 11;16(1):e0243865. doi: 10.1371/journal.pone.0243865. eCollection 2021.

Abstract

OBJECTIVE

To determine the effectiveness of pharmacologic interventions for preventing postoperative nausea and vomiting (PONV) in patients undergoing thyroidectomy.

DESIGN

Systematic review and network meta-analysis (NMA).

DATA SOURCES

MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and Google Scholar.

ELIGIBILITY CRITERIA, PARTICIPANTS, AND INTERVENTIONS: Randomized clinical trials that investigated the efficacy of pharmacologic interventions in preventing PONV in patients undergoing thyroidectomy were included. The primary endpoints were the incidences of postoperative nausea and vomiting (PONV), postoperative nausea (PON), postoperative vomiting (POV), use of rescue antiemetics, and incidence of complete response in the overall postoperative phases. The secondary endpoints were the same parameters assessed in the early, middle, and late postoperative phases. The surface under the cumulative ranking curve (SUCRA) values and rankograms were used to present the hierarchy of pharmacologic interventions.

RESULTS

Twenty-six studies (n = 3,467 patients) that investigated 17 different pharmacologic interventions were included. According to the SUCRA values, the incidence of PONV among the overall postoperative phases was lowest with propofol alone (16.1%), followed by palonosetron (27.5%), and with tropisetron (28.7%). The incidence of PON among the overall postoperative phases was lowest with propofol alone (11.8%), followed by tropisetron and propofol combination (14%), and ramosetron and dexamethasone combination (18.0%). The incidence of POV among the overall postoperative phases was lowest with tropisetron and propofol combination (2.2%), followed by ramosetron and dexamethasone combination (23.2%), and tropisetron alone (37.3%). The least usage of rescue antiemetics among the overall postoperative phases and the highest complete response was observed with tropisetron and propofol combination (3.9% and 96.6%, respectively).

CONCLUSION

Propofol and tropisetron alone and in combination, and the ramosetron and dexamethasone combination effectively prevented PONV, PON, POV in patients undergoing thyroidectomy, with some heterogeneity observed in this NMA of full-text reports. Their use minimized the need for rescue antiemetics and enhanced the complete response.

TRIAL REGISTRATION NUMBER

CRD42018100002.

摘要

目的

确定预防甲状腺切除术患者术后恶心和呕吐(PONV)的药物干预措施的有效性。

设计

系统评价和网络荟萃分析(NMA)。

数据来源

MEDLINE、EMBASE、Cochrane 对照试验中心注册库和 Google Scholar。

入选标准、参与者和干预措施:纳入了研究预防甲状腺切除术患者 PONV 的药物干预措施的疗效的随机临床试验。主要终点是术后恶心(PONV)、术后恶心(PON)、术后呕吐(POV)、使用解救性止吐药和整个术后阶段的完全反应发生率。次要终点是早期、中期和晚期术后阶段评估的相同参数。表面下累积排名曲线(SUCRA)值和等级图用于呈现药物干预措施的层次结构。

结果

共纳入 26 项研究(n=3467 名患者),研究了 17 种不同的药物干预措施。根据 SUCRA 值,在整个术后阶段,PONV 的发生率最低的是单独使用丙泊酚(16.1%),其次是帕洛诺司琼(27.5%)和托烷司琼(28.7%)。在整个术后阶段,PON 的发生率最低的是单独使用丙泊酚(11.8%),其次是托烷司琼和丙泊酚联合使用(14%),以及雷莫司琼和地塞米松联合使用(18.0%)。在整个术后阶段,POV 的发生率最低的是托烷司琼和丙泊酚联合使用(2.2%),其次是雷莫司琼和地塞米松联合使用(23.2%)和托烷司琼单独使用(37.3%)。在整个术后阶段,解救性止吐药的使用最少,完全反应率最高的是托烷司琼和丙泊酚联合使用(分别为 3.9%和 96.6%)。

结论

单独和联合使用丙泊酚和托烷司琼以及雷莫司琼和地塞米松联合可有效预防甲状腺切除术患者的 PONV、PON、POV,该 NMA 对全文报告的异质性进行了观察。它们的使用最大限度地减少了对解救性止吐药的需求,并提高了完全反应率。

试验注册号

CRD42018100002。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c869/7799806/f9661db7ec98/pone.0243865.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验